Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Alzheimer Dis Assoc Disord. 2019 Apr-Jun;33(2):104–112. doi: 10.1097/WAD.0000000000000303

Figure 1.

Figure 1.

Power curves for trials incorporating the CDRSB (A-F) and ADAS13 (G-L) as primary outcomes. In the rows 1 (A-C) and 3 (G-I), power is plotted for trials using indicated biomarker inclusion criteria (and the associated sample sizes based on ADNI) for varying estimated treatment effects. The dotted horizontal line indicates 90% power. In rows 2 (D-F) and 4 (J-L), relative power is plotted, using trials enrolling based only on CSF Aβ as a reference.